PD-1 blockade induces responses by inhibiting adaptive immune resistance
- PMID: 25428505
- PMCID: PMC4246418
- DOI: 10.1038/nature13954
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Abstract
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8(+) T cells (termed adaptive immune resistance). Here we show that pre-existing CD8(+) T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8(+) T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8(+) T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.
Figures
Similar articles
-
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16. Clin Cancer Res. 2017. PMID: 28512174
-
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14. Lancet Oncol. 2018. PMID: 30120041
-
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.Int J Oncol. 2017 Jan;50(1):41-48. doi: 10.3892/ijo.2016.3785. Epub 2016 Dec 2. Int J Oncol. 2017. PMID: 27922697 Free PMC article.
-
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24029602 Review.
-
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Clin Cancer Res. 2013. PMID: 24089443 Review.
Cited by
-
CD34 as a potential prognostic indicator for camrelizumab response in advanced non-small-cell lung cancer: insights from digital spatial profiling.Ther Adv Med Oncol. 2024 Oct 17;16:17588359241289671. doi: 10.1177/17588359241289671. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39429466 Free PMC article.
-
Statistical analysis of multiple regions-of-interest in multiplexed spatial proteomics data.Brief Bioinform. 2024 Sep 23;25(6):bbae522. doi: 10.1093/bib/bbae522. Brief Bioinform. 2024. PMID: 39428129 Free PMC article.
-
Cold and hot tumors: from molecular mechanisms to targeted therapy.Signal Transduct Target Ther. 2024 Oct 18;9(1):274. doi: 10.1038/s41392-024-01979-x. Signal Transduct Target Ther. 2024. PMID: 39420203 Free PMC article. Review.
-
Baseline absolute lymphocyte count as a prognostic indicator in advanced or metastatic breast cancer: a systematic review and meta-analysis.Am J Transl Res. 2024 Sep 15;16(9):5049-5062. doi: 10.62347/ZXWY3004. eCollection 2024. Am J Transl Res. 2024. PMID: 39398610 Free PMC article.
-
Consensus, debate, and prospective on pancreatic cancer treatments.J Hematol Oncol. 2024 Oct 10;17(1):92. doi: 10.1186/s13045-024-01613-x. J Hematol Oncol. 2024. PMID: 39390609 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials